Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics

被引：5

作者：

Jiang, Xia ^{[1
,2
,3
]}

Li, Dabing ^{[1
,4
]}

Maghsoudloo, Mazaher ^{[1
]}

Zhang, Xinghai ^{[5
]}

Ma, Wenzhe ^{[3
]}

Fu, Junjiang ^{[1
,2
]}

机构：

[1] Southwest Med Univ, Res Ctr Preclin Med, Key Lab Epigenet & Oncol, Luzhou, Peoples R China

[2] Southwest Med Univ, Dept Reprod Med, Affiliated Hosp, Luzhou, Sichuan, Peoples R China

[3] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China

[4] Southwest Med Univ, Sch Basic Med Sci, Luzhou, Sichuan, Peoples R China

[5] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, CAS Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China

来源：

DRUG DISCOVERY TODAY | 2024年 / 29卷 / 07期

基金：

中国国家自然科学基金;

关键词：

SARS-CoV-2; furin; COVID-19; furin inhibitors; therapeutics; CRYSTAL-STRUCTURES; POTENT INHIBITORS; SPIKE PROTEIN; CORONAVIRUS; CLEAVAGE; GLYCOPROTEIN; FUSION; VIRUS; ACTIVATION; SEQUENCE;

D O I：

10.1016/j.drudis.2024.104026

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

SARS-CoV-2 has triggered an international outbreak of the highly contagious acute respiratory disease known as COVID-19. Identifying key targets in the virus infection lifecycle is crucial for developing effective prevention and therapeutic strategies against it. Furin is a serine endoprotease that belongs to the family of proprotein convertases and plays a critical role in the entry of host cells by SARSCoV-2. Furin can cleave a speci fic S1/S2 site, PRRAR, on the spike protein of SARS-CoV-2, which promotes viral transmission by facilitating membrane fusion. Hence, targeting furin could hold clinical implications for the prevention and treatment of COVID-19. This review offers an overview of furin 's structure, substrates, function, and inhibitors, with a focus on its potential role in SARS-CoV-2 infection.

引用

页数：16

共 50 条

[41] COVID-19: potential therapeutics for pediatric patients
Nour K. Younis
Rana O. Zareef
Ghina Fakhri
Fadi Bitar
Ali H. Eid
Mariam Arabi
Pharmacological Reports, 2021, 73 : 1520 - 1538
[42] Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Chauhan, Gaurav
Madou, Marc J.
Kalra, Sourav
Chopra, Vianni
Ghosh, Deepa
Martinez-Chapa, Sergio O.
ACS NANO, 2020, 14 (07) : 7760 - 7782
[43] COVID-19: A review of therapeutics under investigation
Crosby, James C.
Heimann, Matthew A.
Burleson, Samuel L.
Anzalone, Brendan C.
Swanson, Jonathan F.
Wallace, Douglas W.
Greene, Christopher J.
JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2020, 1 (03) : 231 - 237
[44] Exosome therapeutics for COVID-19 and respiratory viruses
Popowski, Kristen D.
Dinh, Phuong-Uyen C.
George, Arianna
Lutz, Halle
Cheng, Ke
VIEW, 2021, 2 (03)
[45] Combination prevention for COVID-19
Cohen, Myron S.
Corey, Lawrence
SCIENCE, 2020, 368 (6491) : 551 - 551
[46] Cardiovascular prevention and COVID-19
Volpe, Massimo
Battistoni, Allegra
GIORNALE ITALIANO DI CARDIOLOGIA, 2021, 22 (05) : E1 - +
[47] Suicide prevention and COVID-19
Ivbijaro, Gabriel
Kolkiewicz, Lucja
Goldberg, David
N'jie, Isatou N. S.
Edwards, Todd
Riba, Michelle B.
Svab, Igor
Geller, Jeffrey
Enum, Yaccub
ASIA-PACIFIC PSYCHIATRY, 2021, 13 (03)
[48] Cardiovascular system and COVID-19: manifestations and therapeutics
Mahenthiran, Ajay K.
Mahenthiran, Ashorne K.
Mahenthiran, Jo
REVIEWS IN CARDIOVASCULAR MEDICINE, 2020, 21 (03) : 399 - 409
[49] Vaccines and therapeutics for immunocompromised patients with COVID-19
Shoham, Shmuel
Batista, Carolina
Ben Amor, Yanis
Ergonul, Onder
Hassanain, Mazen
Hotez, Peter
Kang, Gagandeep
Kim, Jerome H.
Lall, Bhavna
Larson, Heidi J.
Naniche, Denise
Sheahan, Timothy
Strub-Wourgaft, Nathalie
Sow, Samba O.
Wilder-Smith, Annelies
Yadav, Prashant
Bottazzi, Maria Elena
ECLINICALMEDICINE, 2023, 59
[50] The Equitable Distribution of COVID-19 Therapeutics and Vaccines
Bollyky, Thomas J.
Gostin, Lawrence O.
Hamburg, Margaret A.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (24): : 2462 - 2463

← 1 2 3 4 5 →